Research Paper Volume 13, Issue 4 pp 5485—5505

Tumor microenvironment characterization in triple-negative breast cancer identifies prognostic gene signature

TME Clusters of Triple-negative breast cancer. (A) TNBC TME clusters in training set. Unsupervised clustering of tumor microenvironment immune cells for 107 TNBC patients from training set. Clinicopathological information including age, MFS, OS, as well as TME clusters, is shown in annotations above. (B) TNBC TME clustering in the validation set. Unsupervised clustering of tumor microenvironmental immune cells from 299 cases of TNBC from validation set. The OS and the number of months of survival are shown in the comments above. (C) Kaplan–Meier curves for Metastasis-free survival (MFS) stratified by TME clusters in the GEO cohort. (D) Kaplan–Meier curves for overall survival (OS) stratified by TME clusters in the training set. Hierarchical clustering was performed using Euclidean distance and ward linkage. (E) Kaplan–Meier curves for overall survival (OS) stratified by TME clusters in the validation set. (F) The abundance of immune-related terms in the Cluster 1 and 2.

Figure 1. TME Clusters of Triple-negative breast cancer. (A) TNBC TME clusters in training set. Unsupervised clustering of tumor microenvironment immune cells for 107 TNBC patients from training set. Clinicopathological information including age, MFS, OS, as well as TME clusters, is shown in annotations above. (B) TNBC TME clustering in the validation set. Unsupervised clustering of tumor microenvironmental immune cells from 299 cases of TNBC from validation set. The OS and the number of months of survival are shown in the comments above. (C) Kaplan–Meier curves for Metastasis-free survival (MFS) stratified by TME clusters in the GEO cohort. (D) Kaplan–Meier curves for overall survival (OS) stratified by TME clusters in the training set. Hierarchical clustering was performed using Euclidean distance and ward linkage. (E) Kaplan–Meier curves for overall survival (OS) stratified by TME clusters in the validation set. (F) The abundance of immune-related terms in the Cluster 1 and 2.